


New treatment seeking to prevent COVID-19

The HERD clinical trial led by MELISA Institute in Chile aims to evaluate the safety and efficacy of Previfenon®


PREVIFENON®

It is an oral formulation whose active ingredient is EGCG (epigallocatechin gallate), stabilized with zinc salts and excipients.




EGCG-ZINC COMPLEXES

The combined use of both molecules promotes an increased cellular absorption; which is less effective if used separately.




HEPATIC PROTECTION

EGCG-zinc complexes increase the protective activity of EGCG on hepatocytes, making it more tolerable and safe.



ANTI-INFLAMMATORY EFFECT

EGCG activates regulatory T cells that produce interleukin-10 (IL-10), which may eventually prevent a cytokine storm, with severe autoimmune symptoms.



How the study is conducted

Design of the HERD clinical trial to determine the efficacy of Previfenon® in preventing COVID-19 and to evaluate its liver safety profile.

Minimum sample:

524 health workers exposed to covid-19 from hospitals in Chile, Argentina and Mexico.

From hospitals with at least **70%** of the beds occupied by patients with covid-19.



Divided into two groups

Treatment
Takes Previfenon® as preventive treatment.

Control group
Takes placebo (substance with no effect).

Double blind: neither the researchers nor the patients know what they are taking.

